Theriva Biologics, Inc. Retained Earnings
Theriva Biologics, Inc. (TOVX) had Retained Earnings of -$363.97 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$363.97M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$360.75M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$358.71M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$356.71M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$363.97M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$360.75M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | -$358.71M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$356.71M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$352.35M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | -$339.30M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$334.97M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$330.52M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$322.80M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | -$314.48M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$309.32M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$303.83M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | -$300.53M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | -$295.45M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | -$290.97M 10-K · filed 2024-03-25 | |
| 2022-09-30 | -$284.52M 10-K · filed 2023-03-30 | -$285.38M 10-Q · filed 2022-11-10 |
| 2022-06-30 | -$280.03M 10-K · filed 2023-03-30 | -$280.52M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$275.56M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | -$271.28M 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$266.02M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | -$262.75M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | -$259.55M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | -$248.09M 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$244.97M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | -$242.29M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | -$238.97M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | -$235.54M 10-K · filed 2021-03-04 | |
| 2019-09-30 | -$232.39M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | -$227.14M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | -$223.43M 10-Q · filed 2019-05-08 | |
| 2018-12-31 | -$219.46M 10-K · filed 2020-02-20 | |
| 2018-09-30 | -$204.54M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | -$200.80M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | -$196.54M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | -$194.17M 10-K · filed 2019-02-27 | |
| 2017-09-30 | -$196.96M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | -$179.13M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | -$174.88M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | -$172.03M 10-K · filed 2018-02-22 | |
| 2016-09-30 | -$169.66M 10-Q · filed 2016-11-01 | |
| 2016-06-30 | -$161.31M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | -$155.62M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | -$144.78M 10-K · filed 2017-03-02 | |
| 2015-09-30 | -$133.80M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | -$127.02M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$113.40M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$101.04M 10-K · filed 2016-03-10 | |
| 2014-09-30 | -$94.56M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | -$89.65M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$85.10M 10-Q · filed 2014-05-15 | |
| 2013-12-31 | -$81.26M 10-K · filed 2015-03-16 | |
| 2013-09-30 | -$77.03M 10-Q · filed 2013-11-14 | |
| 2013-06-30 | -$73.67M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | -$71.17M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | -$68.94M 10-K · filed 2014-03-31 | |
| 2012-09-30 | -$56.88M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | -$54.95M 10-Q/A · filed 2012-09-11 | |
| 2012-03-31 | -$53.07M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | -$51.87M 10-K · filed 2013-04-16 | |
| 2011-09-30 | -$48.69M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | -$47.59M 10-Q · filed 2011-08-15 | |
| 2010-12-31 | -$43.72M 10-K/A · filed 2012-05-11 | -$43.72M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |